Page 23 - Effective Time News Today

Item 1.01 Entry Into a Material Definitive Agreement Agreement and Plan of Merger On March 30, 2023, Diffusion Pharmaceuticals Inc., a Delaware corporation , entered into an Agreement and Plan of... | March 30, 2023

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On March 28, 2023, Ensysce Biosciences, Inc. filed an amendment to the Companys Third Amended and Restated... | March 30, 2023

The following discussion and analysis provide information which we believe is relevant to an assessment and understanding of our audited consolidated results of operations and financial condition. You... | March 29, 2023

The instructions accompanying this Letter of Transmittal should be read carefully before this Letter of Transmittal is completed. LETTER OF TRANSMITTAL ... | March 29, 2023

You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and notes thereto for the... | March 27, 2023

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our accompanying consolidated financial statements and the related notes... | March 24, 2023

Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a

Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical... | March 24, 2023

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | March 24, 2023

You should read the following discussion and analysis of our financial condition and results of operations together with our audited annual consolidated financial statements as of December 31, 2022... | March 24, 2023